This trial is conducted in Europe, Asia, North America and South America. The aim of this research trial is to compare the efficacy of inhaled insulin to glimepiride and metformin combination therapy in treatment of subjects with type 2 diabetes and to verify the safety of use (hypoglycaemia, pulmonary function, body weight, insulin antibodies and side effects).
The decision to discontinue the development of AERx® is not due to any safety concerns. An analysis concluded that fast-acting inhaled insulin in the form it is known today, is unlikely to offer significant clinical or convenience benefits over injections of modern insulin with pen devices.
Treat-to-target dose titration scheme, pre-prandial, inhalation.
Tablets, 2000 mg/day.
Tablets, 4 mg/day.
Treat-to-target dose titration scheme, post-prandial, inhalation.
Buenos Aires, Argentina
Buenos Aires, Argentina
Mar del Plata, Argentina
Mendoza, Argentina